Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ubidecarenone + gemcitabine
- Development stage
- Unknown
- Lead developer
- Berg
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Ubidecarenone + gemcitabine** is an investigational combination therapy consisting of **ubidecarenone** (the USP name for coenzyme Q10) formulated as a nanosuspension (BPM31510) and the cytotoxic antimetabolite chemotherapy **gemcitabine**. Ubidecarenone acts on mitochondrial metabolism, impacting metabolic and redox homeostasis in cancer cells, while gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to apoptosis. The combination is currently being evaluated for efficacy in **advanced pancreatic cancer**, with the hypothesis that mitochondrial targeting by ubidecarenone may sensitize tumor cells to gemcitabine-induced cytotoxicity and improve clinical outcomes[2][5][7].
- Other names
- coenzyme Q10 + gemcitabine
02
Targets
RNR (Ribonucleotide reductase)ND1 (Mitochondrial electron transport chain complex I)DNA polymerase family
Beyond the preview
Go deeper on ubidecarenone + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ubidecarenone + gemcitabine.